Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

References

• Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014;35:3033-69, 3069a–3069k
   PubMed Web of Science ®Google Scholar
• Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-2
   PubMed Web of Science ®Google Scholar
• Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-64
   PubMed Web of Science ®Google Scholar
• Lambooij MS, Drewes HW. Risico's en gebrekkige afstemming in de trombosezorg. Rijksinstituut voor Volksgezondheid en Milieu 2010, Bilthoven, the Netherlands
   Google Scholar
• Surie S, van Delden OM, Kloek JJ, et al. Chronic thrombo-embolic pulmonary hypertension. Ned Tijdschr Geneeskd 2010;154:A1452
   PubMedGoogle Scholar
• Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8
   PubMed Web of Science ®Google Scholar
• Oudega R, Van Weert H, Stoffers H, et al. NHG-Standaard Diepe veneuze trombose M86. Huisarts Wet 2008;51:24-37
   Google Scholar
• Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4
   PubMed Web of Science ®Google Scholar
• Locadia M, Bossuyt PMM, Stalmeier PFM, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost 2004;92:1336-41
   PubMed Web of Science ®Google Scholar
• Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005;165:1173-8
   PubMedGoogle Scholar
• Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64
   PubMed Web of Science ®Google Scholar
• Miniati M, Monti S, Bottai M, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006;85:253-62
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006;130:172-5
   PubMed Web of Science ®Google Scholar
• Klok FA, van Kralingen KW, van Dijk APJ, et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010;95:970-5
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-8
   PubMed Web of Science ®Google Scholar
• Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. The American Association for Thoracic Surgery 2011;141:702-10
   PubMed Web of Science ®Google Scholar
• Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011;14:65-74
   PubMedGoogle Scholar
• Prandoni P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol 2012;88:185-94
   PubMed Web of Science ®Google Scholar
• Zorginstituut Nederland. Farmacotherapeutisch Kompas [Internet] 2015. Diemen, the Netherlands: Zorginstituut Nederland. www.farmacotherapeutischkompas.nl. Accessed January 1, 2017
   Google Scholar
• Michels J, Demulder A, Dirven K, et al. Orale Anticoagulatietherapie door de Huisarts: Gevalideerd door CEBAM in november 2009. Domus Medica vzw, bijlage bij Huisarts Nu. 2010;S1-S36
   Google Scholar
• Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn Diagnostiek, Preventie en Behandeling van veneuze Trombo-Embolie en secundaire Preventie Arteriele Trombose. Utrecht, The Netherlands: Kwaliteitsinstituut voor de Gezondheidszorg CBO; 2008
   Google Scholar
• Büller HR, Prins MH, Lensin AWA, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21
   PubMedGoogle Scholar
• Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective. Thromb Res 2013;132:647-51
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64
   PubMedGoogle Scholar
• Santos IF, Pereira S, McLeod E, et al. Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal. Acta Med Port 2014;27:615-24
   PubMed Web of Science ®Google Scholar
• Bamber L, Muston D, Mcleod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J 2015;13:1-12
   PubMedGoogle Scholar
• College voor Zorgverzekeringen (CVZ). Beoordeling uitbreiding indicatie rivaroxaban (Xarelto(R)). CVZ; 2014. Diemen, the Netherlands
   Google Scholar
• College voor Zorgverzekeringen (CVZ). CFH-rapport 12/13: Rivaroxaban (Xarelto(R)). CVZ; 2012. Diemen, the Netherlands
   Google Scholar
• Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Zorginstituut Nederland; 2015. Diemen, the Netherlands
   Google Scholar
• Geersing G-J, Janssen K, Oudega R, et al. Diagnostic classification in patients with suspected deep venous thrombosis: physicians’ judgement or a decision rule? Br J Gen Pract 2010;60:742-8
   PubMed Web of Science ®Google Scholar
• Zondag W, Mos ICM, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9:1500-7
   PubMed Web of Science ®Google Scholar
• Federatie van Nederlandse Trombosediensten. Samenvatting medische jaarverslagen 2014. Voorschoten, the Netherlands
   Google Scholar
• Blann A, Hewitt J, Siddiqui F, et al. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999;107:207-9
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Atrial fibrillation: the management of atrial fibrillation. Clinical guideline no. 36. Primary Care. NICE; 2006. London/ Manchester, United Kingdom
   Google Scholar
• Aujesky D, Smith KJ, Cornuz J, et al. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005;128:1601-10
   PubMed Web of Science ®Google Scholar
• Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 2005;118:625-35
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Berto P, Prandoni P. Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism. Expert Rev Pharmacoecon Outcomes Res 2006;6:249-59
   PubMedGoogle Scholar
• Marchetti M, Pistorio A, Barone M, et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001;111:130-9
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Caro I, et al. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 2002;20:593-602
   PubMed Web of Science ®Google Scholar
• Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205
   PubMed Web of Science ®Google Scholar
• Linkins L, O’Donnell M, Julian JA, et al. Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy. J Thromb Haemost 2010;8:2201-7
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JSR, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1122-7
   PubMed Web of Science ®Google Scholar
• Centraal Bureau voor de Statistiek (CBS). Overledenen; doodsoorzaak (uitgebreide lijst), leeftijd, geslacht, 2015. Den Haag, the Netherlands. http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=7233&D1=0,639,659-660,685-687,1304&D2=a&D3=a&D4=l&HDR=T&STB=G1,G2,G3&VW=T. Accessed January 1, 2015
   Google Scholar
• Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006;1132:1121-32
   Web of Science ®Google Scholar
• Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res. 2015;135:281-8
   PubMed Web of Science ®Google Scholar
• Bamber L, Cano SJ, Lamping DL, et al. Patient-reported treatment satisfaction with oral rivaroxaban vs. standard therapy in the treatment of symptomatic deep vein thrombosis (DVT). Int Soc Thromb Haemostas 2011;9(Suppl 2):P-TH-284
   Google Scholar
• Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study.J Health Serv Res Policy. 2001;6:92-8
   PubMedGoogle Scholar
• Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31:800-4
   PubMed Web of Science ®Google Scholar
• Baeten SA, van Exel NJA, Dirks M, et al. Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc 2010;8:21
   PubMedGoogle Scholar
• Meads DM, McKenna SP, Doughty N, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J Off J Eur Soc Clin Respir Physiol 2008;32:1513-9
   PubMed Web of Science ®Google Scholar
• NICE. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Development 2010. National Institute for Health and Care Excellence (NICE). Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Clinical guideline CG92, 2010. NICE, London/Manchester, United Kingdom
   Google Scholar
• McKenna SP, Ratcliffe J, Meads DM, et al. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes. 2008;6:65
   PubMed Web of Science ®Google Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis. J Am Med Informatics Assoc 1997;4:49-56
   PubMed Web of Science ®Google Scholar
• Netherlands Health Care Institute. Drug Information System [Internet]. http://www.gipdatabank.nl, Zorginstituut Nederland, Diemen, the Netherlands. Accessed January 1, 2016.
   Google Scholar
• Ten Cate-Hoek AJ, Toll DB, Büller HR, et al. Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost. 2009;7:2042-9
   PubMed Web of Science ®Google Scholar
• Nederlandse Zorgautoriteit (NZA). Beleidsregel TB/CU-2066-01, Prestatie- en tariefbeschikking DOT. NZA; 2016. Utrecht, the Netherlands
   Google Scholar
• Van Leent MWJ, Stevanović J, Jansman FG, et al. Cost-effectiveness of dabigatran compared to vitamin-K antagonists for the treatment of deep venous thrombosis in the Netherlands using real-world data. PLoS One. 2015;10:e0135054
   PubMed Web of Science ®Google Scholar
• Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, et al. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 2015. Zorginstituut Nederland, Diemen, the Netherlands
   Google Scholar
• Federatie van Nederlandse Trombosediensten. Samenvatting medische jaarverslagen 2013. Voorschoten, the Netherlands
   Google Scholar
• Vonkeman HE, Klok RM, Postma MJ, et al. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging. 2007;24:681-90
   PubMed Web of Science ®Google Scholar
• Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health. International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2003;6:59-74
   PubMed Web of Science ®Google Scholar
• Sociaal en Cultureel Planbureau. Nederland deeltijdland. Vrouwen en deeltijdwerk. Den Haag, The Netherlands: Sociaal en Cultureel Planbureau; 2008
   Google Scholar
• College van Toezicht Sociale Verzekeringen. Bestanden ziekteverzuim uit de diagnostatistiek ziekengeldenverzekering 1993. Zoetermeer: College van Toezicht Sociale Verzekeringen; 2006
   Google Scholar
• National Board of Health and Welfare. Swedish Health and Welfare Statistical Databases [Internet]. 2009. Stockholm, Sweden. http://www.socialstyrelsen.se/Statistik/statistikdatabas. Accessed January 1, 2013
   Google Scholar
• Ericson L, Bergfeldt L, Björholt I. Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ. 2011;12:479-87
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 341; 2015. London/Manchester, United Kingdom
   Google Scholar
• Scottish Medicines Consortium (SMC). Apixaban, 2.5mg & 5mg, film-coated tablets (Eliquis®). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. SMC No. (1029/15); 2015. Glasgow, United Kingdom
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 327; 2014. London/Manchester, United Kingdom
   Google Scholar
• Scottish Medicines Consortium (SMC). Dabigatran etexilate, 110mg, 150mg capsules (Pradaxa®). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. SMC No. (995/14); 2014. Glasgow, United Kingdom
   Google Scholar
• Zorginstituut Nederland. Farmaco-economisch (FE) rapport voor dabigatran Pradaxa(R) bij de behandeling van diep veneuze trombose (DVT) en pulmonaire embolie (PE) en preventie van recidief DVT en PE. 2015. Diemen, the Netherlands
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261; 2012. London/Manchester, United Kingdom
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287; 2013. London/Manchester, United Kingdom
   Google Scholar
• College voor Zorgverzekeringen (CVZ). CFH-rapport 09/03: Rivaroxaban (Xarelto (R)). 2009. Diemen, the Netherlands
   Google Scholar
• College voor Zorgverzekeringen (CVZ). CFH-rapport 08/16: dabigatran (Pradaxa (R)). 2008. Diemen, the Netherlands
   Google Scholar
• Michels J, Demulder A, Dirven K. Aanbeveling voor goede medische praktijkvoering: Orale anticoagulatietherapie door de huisarts. Huisarts Nu 2010;39:S1-S36
   Google Scholar
• Van Leeuwen Y, Rosendaal FR, van der Meer FJM. The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon. Thromb Res 2008;123:225-30
   PubMed Web of Science ®Google Scholar
• Bezemer ID, Van den Berg EJ, Folkerts K, et al. Anticoagulation treatment after VTE in the Netherlands. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Boston, MA: International Society for Pharmacoepidemiology; 2015. p. 134
   Google Scholar